Oncology Research and Care: Reimagining Digital Innovation

Jeremy Wyatt, Chief Executive Officer, ActiGraph

Jeremy Wyatt is the CEO of ActiGraph, a leading global provider of physical activity and sleep monitoring solutions for pharmaceutical and academic industries. With two decades of embedded hardware systems development and related cloud technology expertise, Jeremy has a uniquely well-rounded perspective on the challenges and opportunities of deploying wearable technologies to capture accurate and meaningful patient data.

He is considered an industry thought leader and expert in the clinical biosensor space and is a frequent representative and contributor at clinical drug development commercial events, scientific consortiums and FDA/EMA regulatory meetings. He has an undergraduate degree in electrical engineering from the University of Florida and an MBA from the University of West Florida. Jeremy is a member and contributor to the Digital Medicine (DiMe) Society and participates in various digital biomarker efforts with the Clinical Trial Transformation Initiative (CTTI).

Kate Lyden, PhD, Chief Science Officer, VivoSense

Kate Lyden, PhD is the Chief Science Officer for VivoSense, an agile end-to-end solutions company measuring patient outcomes by developing novel digital endpoints from wearable sensor data. Kate has an extensive and diverse background in the development and implementation of wearable sensor methodologies across clinical, academic, and industry settings. She is passionate about leveraging the power of connected sensor technologies to gain meaningful insights into real-world patient behaviors and experiences. Prior to joining VivoSense, Kate spent nearly ten years as an academic researcher focused on synchronizing continuous measures of real-world behavior with physiological signals to reveal associations between important health behaviors and risk for chronic disease. She has authored many scientific publications on the objective measurement of human behaviors and is a frequent contributor and collaborator on this topic at clinical development commercial events and industry working groups.

Ariel Aguiló, MD, Executive Medical Director, Head of the Americas Oncology Medical Team, Labcorp Drug Development

Ariel Aguiló, MD, is a board-certified oncologist specialized in gastrointestinal tumors. He is an Executive Medical Director and Head of the Americas Oncology Medical Team for Labcorp Drug Development, based in Buenos Aires, Argentina. He brings more than 10 years of experience as a physician and vast experience leading global trials. He also provides subject matter expertise and support for the development and conduct of clinical trials on client’s drug development projects.

Jorge Nieva, Associate Professor of Clinical Medicine, Keck School of Medicine of USC

Dr. Jorge Nieva is the section head of solid tumors, division of medical oncology at the Keck School of Medicine and director of the lung cancer research program within the USC/Norris Cancer Center. He serves as the chair of the data and safety monitoring committee at the cancer center and leads the internal advisory committee for the CARE2 Health Equity Center at USC. Dr. Nieva is an expert in biomarker development and informatic approaches to the evaluation of patient health. He is a graduate of the University of California Irvine College of Medicine, trained internal medicine at the University of California, San Diego and in Oncology/Hematology at the Scripps Clinic.  Prior to joining the faculty at USC, he was on the faculty at the Scripps Research Institute and the Billings Clinic.

Heather Jim, Ph.D. Senior Member and Co-Leader, Health Outcomes and Behavior Program, Moffitt Cancer Center

Heather Jim Ph.D. is a Senior Member and Co-Leader of the Health Outcomes and Behavior Program at Moffitt Cancer Center.  Her research focuses on the psychological and physical effects of cancer diagnosis and treatment.  She has four lines of research dedicated to: 1) documenting the prevalence, severity, and chronicity of side effects of cancer and its treatment, 2) determining which patients are at the greatest risk of developing side effects, 3) understanding underlying biological and behavioral mechanisms, and 4) developing and evaluating targeted interventions to prevent or reduce side effects.  She has published extensively on these topics and has an active program of federally-funded research.